As a leading CDMO and CRO partner for antibody-drug conjugates (ADCs), Abzena offers fully integrated solutions spanning early-stage R&D through to commercial manufacturing. With two decades of experience, the company supports programs from discovery to IND and beyond, combining antibody engineering, linker-payload design, bioconjugation and GMP manufacturing within a single organization.
Abzena’s proprietary technologies, including ThioBridge™, enable precise site-specific conjugation for enhanced stability, scalability, and control of drug-antibody ratios. Its global network of scientists and facilities helps emerging biotechs and large pharma alike accelerate development timelines and reduce risk.
Download the white paper here to read more.
